Immuneering Corp (IMRX)
Healthcare
Biotechnology
4.10 $
-2.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Immuneering Corp (IMRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 76.4% of the shares are freely tradable; institutional investors hold 47.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
47.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
13.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
76.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
28.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
65Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.99 | 9,697,938 | +0.1 | 03/31/2026 |
| Sanofi | 4.19 | 2,708,559 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 3.97 | 2,568,293 | +6.3 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.54 | 2,288,341 | +0.0 | 03/31/2026 |
| Marshall Wace Asset Management Ltd | 3.09 | 1,996,585 | +180.5 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 2.83 | 1,829,188 | -8.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 6.07 | 3,929,008 | +0.8 | 04/30/2026 |
| HBM Healthcare Investments AG Ord | 5.64 | 3,646,304 | +0.0 | 03/31/2026 |
| Fidelity Growth Company Fund | 4.44 | 2,873,177 | +0.9 | 04/30/2026 |
| Vanguard Total Stock Mkt Idx Inv | 2.51 | 1,623,577 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.